Manufacturers Service OEM

Zytogenex USA, Inc. / Plexbio

458 Carlton Court, 94080 South San Franicsco

Telephone +886 2 26275878
Fax +886 2 26275879

This company is co-exhibitor of
Messe Düsseldorf North America


Hall map

MEDICA 2016 hall map (Hall 3): stand D29-8

Fairground map

MEDICA 2016 fairground map: Hall 3

Our range of products

Product categories

  • 03  Diagnostics
  • 03.02  Immunochemistry (Immunology)
  • 03.02.16  Therapeutic drug monitoring

Therapeutic drug monitoring

  • 03  Diagnostics
  • 03.02  Immunochemistry (Immunology)
  • 03.02.16  Therapeutic drug monitoring
  •  Diagnostic agents / kits for determination of therapeutic drugs

Diagnostic agents / kits for determination of therapeutic drugs

Our products

Product category: Therapeutic drug monitoring

IntelliPlex KRAS G12/13 Mutation Kit

PlexBio has developed the IntelliPlex KRAS G12/13 Mutation Kit to detect and identify mutations in codons 12 and 13 of the KRAS gene in samples from patients diagnosed with non-small cell lung cancer (NSCLC) or metastatic colorectal cancer (mCRC) (sample type to be determined by available samples during clinical testing).

More Less

About us

Company details

PlexBio Co., Ltd. was established in May 2010 to design, develop and manufacture IVD products and instrumentations in ISO-certified facilities. To this date, PlexBio has expanded from Asia headquarters in Taipei, Taiwan to Jiangsu Province, China, and has a U.S research facility in San Francisco.

In order to address the issue of rising healthcare costs and an increasing range of available tests, it is crucial for clinical and research labs to consider the cost of labor, sample volume, time and maintenance when it comes to assay formats. Therefore, PlexBio aims to provide a cutting-edge multiplexing platform using our patented Precision Image Code (πCode) MicroDisc technology to overcome this limitation.

Our πCode Microdisc technology is currently the largest multiplexing platform, capable of generating approximately 16,000 circular image patterns. Each image pattern corresponds to an individual target and can be detected simultaneously via advanced optical imaging and fluorescence analyzers. By using our multiplexing platform, we are able to offer highly sensitive and specific results with low sample volumes, which saves time and labor.

Currently, PlexBio is researching and developing high-quality reagents focusing on companion diagnostics, early cancer detection and prenatal diagnostics with ultra-detection sensitivity and fully automated diagnostics instruments for high-throughput clinical needs. With our innovative technologies, PlexBio intends to revolutionize the IVD industry developments, placing PlexBio as the leading brand of global IVD market.

More Less